Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and other investor
February 25, 2021
Share
On February 26, 2021, Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:A000250) closed the transaction.
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and other investor
SAM CHUN DANG PHARM. CO., LTD 
